Neoadjuvant radiotherapy followed by chemotherapy combined with toripalimab immunotherapy in local advanced HR-positive, HER2-negative breast cancer: protocol for a phase II, single-arm, multicenter clinical study
Breast Communications · 2025
DOI: 10.21037/bc-25-3 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Breast Communications, 2025. Verfasst von Anran Pi und 7 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
At present, the efficacy of neoadjuvant systemic therapy (NST) for locally advanced hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer remains suboptimal, even in the combination with immunotherapy of programmed cell death protein 1 (PD-1) inhibitor. Novel clinical approaches are under exploration to increase the therapeutic effect. Research indicates that radiotherapy not only directly kills tumor cells but also reshapes the tumor microenvironment, releasing antigens and inflammatory signals to enhance systemic antitumor immune responses. It was demonstrated that the combination of radiotherapy with PD-1/programmed death-ligand 1 (PD-L1) inhibitors exhibited a synergistic effect, which has not been fully verified in breast cancer. The domestically developed PD-1 inhibitor, toripalimab, has shown promising efficacy and safety, with studies indicating its favorable outcomes in triple-negative breast cancer (TNBC). Thus, our study aims to investigate whether neoadjuvant radiotherapy followed by NST of chemotherapy combined with PD-1 inhibitor immunotherapy could improve the postoperative pathological complete response (pCR) rates and survival for patients with locally advanced HR-positive, HER2-negative breast cancer.
Methods
Thirty patients with local advanced HR-positive, HER2-negative breast cancer will be recruited in this clinical trial. Within three days after enrollment, participants will accept neoadjuvant radiotherapy of stereotactic body radiotherapy (SBRT), with each session of 8 Gy for consecutive 3 days. Then NST of epirubicin-cyclophosphamide for 4 cycles every 3 weeks, followed by weekly nab-paclitaxel for 12 cycles, combined with PD-1 inhibitor toripalimab (at a dose of 240 mg) every 3 weeks for 8 cycles, will be administrated two weeks after neoadjuvant radiotherapy. After definitive surgery, the participants will receive adjuvant toripalimab every 3 weeks for up to ten cycles, alongside with adjuvant radiotherapy and endocrine therapy. The primary endpoint is a pCR rate at the time of definitive surgery evaluated by pathologists.
Discussion
Recent evidence revealed the synergistic effect of radiotherapy and immunotherapy. For local advanced HR-positive, HER2-negative breast cancer, which usually poorly responds to NST, this clinical trial aims to preliminarily explore whether additional neoadjuvant radiotherapy combined with systemic therapy could improve the pCR rate at surgery. Trial Registration: The trial was registered with the Chinese Medical Research Registry (ChiCTR2500104937).
Zitieren
APA
Pi, A., Zhang, D., Yan, S., Tang, Q., Yao, M., Chen, L., Wang, S., & Fu, P. (2025). Neoadjuvant radiotherapy followed by chemotherapy combined with toripalimab immunotherapy in local advanced HR-positive, HER2-negative breast cancer: protocol for a phase II, single-arm, multicenter clinical study. Breast Communications. https://doi.org/10.21037/bc-25-3
Vancouver
Pi A, Zhang D, Yan S, Tang Q, Yao M, Chen L, et al. Neoadjuvant radiotherapy followed by chemotherapy combined with toripalimab immunotherapy in local advanced HR-positive, HER2-negative breast cancer: protocol for a phase II, single-arm, multicenter clinical study. Breast Communications. 2025. doi:10.21037/bc-25-3
BibTeX
@article{Pi2025,
author = {Pi, Anran and Zhang, Di and Yan, Senxiang and Tang, Qiuying and Yao, Minya and Chen, Luyan and Wang, Shuqian and Fu, Peifen},
title = {Neoadjuvant radiotherapy followed by chemotherapy combined with toripalimab immunotherapy in local advanced HR-positive, HER2-negative breast cancer: protocol for a phase II, single-arm, multicenter clinical study},
journal = {Breast Communications},
year = {2025},
doi = {10.21037/bc-25-3}
}
EUVIMED